Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
NCT02932280Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2016
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of neratinib in solid tumor, central nervous system tumor, lymphoma, leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2016; status: active, not recruiting.
02
Drugs
neratinib
03
Conditions
solid tumorcentral nervous system tumorlymphomaleukemia
Beyond the preview
Go deeper on NCT02932280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932280.